An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone

NCT00246272 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
82
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Janssen-Ortho Inc., Canada